112 related articles for article (PubMed ID: 21272753)
21. Practicality of 3D Printed Personalized Medicines in Therapeutics.
Amekyeh H; Tarlochan F; Billa N
Front Pharmacol; 2021; 12():646836. PubMed ID: 33912058
[TBL] [Abstract][Full Text] [Related]
22. Warfarin dosing algorithms: A systematic review.
Asiimwe IG; Zhang EJ; Osanlou R; Jorgensen AL; Pirmohamed M
Br J Clin Pharmacol; 2021 Apr; 87(4):1717-1729. PubMed ID: 33080066
[TBL] [Abstract][Full Text] [Related]
23. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin.
Praxedes MFS; Martins MAP; Mourão AOM; Gomes KB; Reis EA; Souza RP; Campos EIF; Ribeiro DD; Rocha MOC
Eur J Clin Pharmacol; 2020 Feb; 76(2):199-209. PubMed ID: 31720756
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.
Dávila-Fajardo CL; Díaz-Villamarín X; Antúnez-Rodríguez A; Fernández-Gómez AE; García-Navas P; Martínez-González LJ; Dávila-Fajardo JA; Barrera JC
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30939847
[TBL] [Abstract][Full Text] [Related]
25. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective.
Drozda K; Pacanowski MA; Grimstein C; Zineh I
JACC Basic Transl Sci; 2018 Aug; 3(4):545-549. PubMed ID: 30175278
[TBL] [Abstract][Full Text] [Related]
27. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.
Syn NL; Wong AL; Lee SC; Teoh HL; Yip JWL; Seet RC; Yeo WT; Kristanto W; Bee PC; Poon LM; Marban P; Wu TS; Winther MD; Brunham LR; Soong R; Tai BC; Goh BC
BMC Med; 2018 Jul; 16(1):104. PubMed ID: 29986700
[TBL] [Abstract][Full Text] [Related]
28. Emerging Role of Precision Medicine in Cardiovascular Disease.
Leopold JA; Loscalzo J
Circ Res; 2018 Apr; 122(9):1302-1315. PubMed ID: 29700074
[TBL] [Abstract][Full Text] [Related]
29. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
[TBL] [Abstract][Full Text] [Related]
30. Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Kim S; Yun YM; Chae HJ; Cho HJ; Ji M; Kim IS; Wee KA; Lee W; Song SH; Woo HI; Lee SY; Chun S
Ann Lab Med; 2017 Mar; 37(2):180-193. PubMed ID: 28029011
[TBL] [Abstract][Full Text] [Related]
31. Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.
Marchant GE; Scheckel K; Campos-Outcalt D
J Law Med Ethics; 2016 Mar; 44(1):194-204. PubMed ID: 27256135
[TBL] [Abstract][Full Text] [Related]
32. Warfarin Pharmacogenetics: New Life for an Old Drug.
Wen MS; Lee MT
Acta Cardiol Sin; 2013 May; 29(3):235-42. PubMed ID: 27122712
[TBL] [Abstract][Full Text] [Related]
33. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance.
Shahabi P; Scheinfeldt LB; Lynch DE; Schmidlen TJ; Perreault S; Keller MA; Kasper R; Wawak L; Jarvis JP; Gerry NP; Gordon ES; Christman MF; Dubé MP; Gharani N
Thromb Haemost; 2016 Aug; 116(2):337-48. PubMed ID: 27121899
[TBL] [Abstract][Full Text] [Related]
34. Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese population.
Liu R; Zhang K; Gong ZZ; Shi XM; Zhang Q; Pan XD; Dong R
Lipids Health Dis; 2016 Feb; 15():34. PubMed ID: 26912074
[TBL] [Abstract][Full Text] [Related]
35. Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.
Hamadeh IS; Shahin MH; Lima SM; Oliveira F; Wilson L; Khalifa SI; Langaee TY; Cooper-DeHoff RM; Cavallari LH; Johnson JA
Clin Transl Sci; 2016 Feb; 9(1):36-42. PubMed ID: 26751406
[TBL] [Abstract][Full Text] [Related]
36. A multi-factorial analysis of response to warfarin in a UK prospective cohort.
Bourgeois S; Jorgensen A; Zhang EJ; Hanson A; Gillman MS; Bumpstead S; Toh CH; Williamson P; Daly AK; Kamali F; Deloukas P; Pirmohamed M
Genome Med; 2016 Jan; 8(1):2. PubMed ID: 26739746
[TBL] [Abstract][Full Text] [Related]
37. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
Fox CS; Hall JL; Arnett DK; Ashley EA; Delles C; Engler MB; Freeman MW; Johnson JA; Lanfear DE; Liggett SB; Lusis AJ; Loscalzo J; MacRae CA; Musunuru K; Newby LK; O'Donnell CJ; Rich SS; Terzic A;
Circulation; 2015 May; 131(19):1715-36. PubMed ID: 25882488
[TBL] [Abstract][Full Text] [Related]
38. Warfarin pharmacogenetics.
Johnson JA; Cavallari LH
Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
[TBL] [Abstract][Full Text] [Related]
39. Implementation and utilization of genetic testing in personalized medicine.
Abul-Husn NS; Owusu Obeng A; Sanderson SC; Gottesman O; Scott SA
Pharmgenomics Pers Med; 2014; 7():227-40. PubMed ID: 25206309
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics in Jewish populations.
Yang Y; Peter I; Scott SA
Drug Metabol Drug Interact; 2014; 29(4):221-33. PubMed ID: 24867283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
